Several preclinical studies are currently assessing the therapeutic potential of stress granule inhibitors in Kras-driven cancers.[106] Preliminary findings suggest that targeting stress granules can sensitize tumors to chemotherapy and prevent therapy resistance. The gene discussed is KRAS; the disease is cancer.